Program
ivosidenib
Also written as “Ivosidenib”, “Ivosidenib Oral Tablet” and “AG120”.
Its studies are mostly in Cholangiocarcinoma · Leukemia, Myeloid, Acute · Neoplasm Metastasis · Neoplasms, Unknown Primary, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Agios Pharmaceuticals | 50 open or running | phase 1since Jul 1, 2015 | Jul 1, 2015 | none ahead |
| Servier Bio-Innovation | 32 open or running | phase 3since Nov 7, 2023 | Apr 21, 2023 | Feb 1, 2028phase 3 · NCT06127407 |
| Servier Affaires Médicales | 22 open or running | phase 3since May 17, 2023 | May 17, 2023 | Oct 15, 2027phase 3 · NCT05907057 |
| CStone Pharmaceuticals | 10 open or running | phase 1since Oct 29, 2019 | Oct 29, 2019 | none ahead |
| Hoffmann-La Roche | 10 open or running | phase 2since Apr 5, 2018 | Apr 5, 2018 | none ahead |
| Servier | 11 open or running | phase 2since Sep 14, 2023 | Sep 14, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 1, 2015First study: phase 1 study in Healthy VolunteersNew to Agios PharmaceuticalsAgios Pharmaceuticals · NCT02489513 · 8 enrolled · United States
- Oct 15, 2015Phase 1 study in HealthyAgios Pharmaceuticals · NCT02579707 · 36 enrolled · United States
- Jun 9, 2016Phase 1 study in HealthyAgios Pharmaceuticals · NCT02831972 · 22 enrolled · United States
- Mar 2, 2017Phase 1 study in HealthyAgios Pharmaceuticals · NCT03071770 · 60 enrolled · United States
- Sep 8, 2017Phase 1 study in Hepatic ImpairmentAgios Pharmaceuticals · NCT03282513 · 33 enrolled · United States
- Apr 5, 2018Hoffmann-La Roche's first study: phase 2 study in Neoplasms, Unknown PrimaryNew to Hoffmann-La RocheHoffmann-La Roche · NCT03498521 · 529 enrolled · Australia, Austria, Brazil and more
- Oct 29, 2019CStone Pharmaceuticals's first study: phase 1 study in RecurrenceNew to CStone PharmaceuticalsCStone Pharmaceuticals · NCT04176393 · 30 enrolled · China
- Apr 21, 2023Servier Bio-Innovation's first study: phase 2 study in IDH1-mutant CholangiocarcinomaNew to Servier Bio-InnovationServier Bio-Innovation · NCT05921760 · 7 enrolled · United States, United Kingdom
- May 17, 2023Servier Affaires Médicales's first study: phase 3 study in CholangiocarcinomaNew to Servier Affaires MédicalesServier Affaires Médicales · NCT05876754 · 299 enrolled · Armenia, Australia, Austria and more
- Jun 8, 2023Phase 3 study in Leukemia, Myeloid, AcuteServier Affaires Médicales · NCT05907057 · 245 planned · Austria, France, Italy and more
- Sep 14, 2023Servier's first study: phase 2 study in Cholangiocarcinoma Non-resectableNew to ServierServier · NCT06081829 · 12 enrolled · Japan
- Nov 7, 2023Phase 3 study in Neoplasm MetastasisServier Bio-Innovation · NCT06127407 · 156 planned · United States, Australia, Belgium and more
- May 27, 2025Phase 1 study in IDH1-Mutated MalignanciesServier Bio-Innovation · NCT07006688 · 30 planned · United States, Australia, Brazil and more
Ahead
- Oct 15, 2027Primary completion: phase 3 study in Leukemia, Myeloid, AcuteServier Affaires Médicales · NCT05907057
- Dec 1, 2027Primary completion: phase 3 study in CholangiocarcinomaServier Affaires Médicales · NCT05876754
- Feb 1, 2028Primary completion: phase 3 study in Neoplasm MetastasisServier Bio-Innovation · NCT06127407
- Jul 31, 2028Primary completion: phase 1 study in IDH1-Mutated MalignanciesServier Bio-Innovation · NCT07006688
TargetBeta
“An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), ”NCIt, by rule
“Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor”ChEMBL 37, by rule
Other programs on IDH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| olutasidenibrule | Rigel Pharmaceuticals | phase 4 | 5 |
| vorasidenibrule | Agios Pharmaceuticals | phase 3 | 12 |
| ranosidenibrule | HUTCHMED | phase 3 | 7 |
| safusidenibrule | Nuvation Bio | phase 3 | 6 |
| IDH1 Inhibitor TQB3454 | Sino Biopharmaceutical | phase 3 | 5 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07006688IDH1-Mutated Malignancies · United States, Australia, Brazil and more | 1 | Recruiting | Servier Bio-Innovation | Jul 31, 2028 | 30 |
| NCT06127407Neoplasm Metastasis · United States, Australia, Belgium and more | 3 | Recruiting | Servier Bio-Innovation | Feb 1, 2028 | 156 |
| NCT06081829Cholangiocarcinoma Non-resectable · Japan | 2 | Active, not recruiting | Servier | Oct 1, 2024 | 12 |
| NCT05907057Leukemia, Myeloid, Acute · Austria, France, Italy and more | 3 | Recruiting | Servier Affaires Médicales | Oct 15, 2027 | 245 |
| NCT05876754Cholangiocarcinoma · Armenia, Australia, Austria and more | 3 | Active, not recruiting | Servier Affaires Médicales | Dec 1, 2027 | 299 |
| NCT05921760IDH1-mutant Cholangiocarcinoma · United States, United Kingdom | 2 | Terminated | Servier Bio-Innovation | Nov 21, 2024 | 7 |
| NCT04176393Recurrence · China | 1 | Completed | CStone Pharmaceuticals | Feb 18, 2021 | 30 |
| NCT03498521Neoplasms, Unknown Primary · Australia, Austria, Brazil and more | 2 | Completed | Hoffmann-La Roche | Feb 14, 2023 | 529 |
| NCT03282513Hepatic Impairment · United States | 1 | Completed | Agios Pharmaceuticals | Mar 31, 2018 | 33 |
| NCT03071770Healthy · United States | 1 | Completed | Agios Pharmaceuticals | May 9, 2017 | 60 |
| NCT02831972Healthy · United States | 1 | Completed | Agios Pharmaceuticals | Sep 2016 | 22 |
| NCT02579707Healthy · United States | 1 | Completed | Agios Pharmaceuticals | Feb 2016 | 36 |
| NCT02489513Healthy Volunteers · United States | 1 | Completed | Agios Pharmaceuticals | Sep 2015 | 8 |
How it is read
Names in the registry
- “Ivosidenib”, 3 entries
- “Ivosidenib Oral Tablet”, 2 entries
- “AG120”, 2 entries
- “Ivosidenib 500mg”, 1 entry
- “Ivosidenib 500mg Oral Tablet”, 1 entry
Conditions, from the studies’ own filings
- Cholangiocarcinoma, 3 studies
- Leukemia, Myeloid, Acute, 2 studies
- Neoplasm Metastasis, 1 study
- Neoplasms, Unknown Primary, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.